While the main focus of Pfizer Japan Inc.’s annual business update in Tokyo was not surprisingly on the performance, outlook and R&D pipeline of the largest pharma multinational in Japan, the US giant also took the opportunity to present some of its views on ongoing official discussions over drug pricing and reimbursement reforms.
Pointing to the subsidiary’s achievement of 100 new drug approvals in Japan over the past 20 years, and the contribution of these to medical care, country president Ichiro Umeda stressed...